PROSTIN F2 ALPHA Drug Patent Profile

When do Prostin F2 Alpha patents expire, and when can generic versions of Prostin F2 Alpha launch?

Prostin F2 Alpha is a drug marketed by Pharmacia And Upjohn and is included in one NDA.

The generic ingredient in PROSTIN F2 ALPHA is dinoprost tromethamine. There are six drug master file entries for this compound. Additional details are available on the dinoprost tromethamine profile page.

Summary for PROSTIN F2 ALPHA

US Patents:	0
Applicants:	1
NDAs:	1
Raw Ingredient (Bulk) Api Vendors:	59
Clinical Trials:	12
Patent Applications:	498
DailyMed Link:	PROSTIN F2 ALPHA at DailyMed

Recent Clinical Trials for PROSTIN F2 ALPHA

Identify potential brand extensions & 505(b)(2) entrants

Sponsor	Phase
University Medical Centre Maribor	Phase 4
Aswan University Hospital	N/A
National University, Singapore	N/A

See all PROSTIN F2 ALPHA clinical trials

US Patents and Regulatory Information for PROSTIN F2 ALPHA

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Pharmacia And Upjohn	PROSTIN F2 ALPHA	dinoprost tromethamine	INJECTABLE;INJECTION	017434-001	Approved Prior to Jan 1, 1982		DISCN	No	No

Expired US Patents for PROSTIN F2 ALPHA

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	Patent No.	Patent Expiration
Pharmacia And Upjohn	PROSTIN F2 ALPHA	dinoprost tromethamine	INJECTABLE;INJECTION	017434-001	Approved Prior to Jan 1, 1982
Pharmacia And Upjohn	PROSTIN F2 ALPHA	dinoprost tromethamine	INJECTABLE;INJECTION	017434-001	Approved Prior to Jan 1, 1982
Pharmacia And Upjohn	PROSTIN F2 ALPHA	dinoprost tromethamine	INJECTABLE;INJECTION	017434-001	Approved Prior to Jan 1, 1982

International Patents for PROSTIN F2 ALPHA

See the table below for patents covering PROSTIN F2 ALPHA around the world.

Country	Patent Number	Title	Estimated Expiration
Philippines	9218	A PROCESS OF PREPARING PROSTAGLANDIN SALTS OF TRIS(HYDROXYMETHYL)AMINOMETHANE
Denmark	142724
Switzerland	563330
Japan	S5523825
U.S.S.R.	384228
France	2100712

PROSTIN F2 ALPHA Market Analysis and Financial Projection

Last updated: April 26, 2026

PROSTIN F2 ALPHA: Market Dynamics and Financial Trajectory

PROSTIN F2 ALPHA (prostaglandin F2α; commonly “dinoprost” as dinoprost tromethamine in branded products) is a niche specialty pharmaceutical with demand concentrated in specific clinical indications and geographies. Its market trajectory is shaped by high regulatory exposure, limited indication breadth relative to broader oncology and anti-infective franchises, and competitive pressure from alternative prostaglandin products and generic erosion where approvals permit. Financial performance typically tracks usage intensity in constrained settings rather than volume-led blockbuster growth.

Because “PROSTIN F2 ALPHA” is a brand name used for dinoprostone/prostaglandin F2α products in some markets, a fully grounded market sizing and revenue forecast depends on the exact marketed product (strength, dosage form, NDC/MAH, and regulatory approvals) and the year-level dataset. With only the brand name provided, an accurate, number-based financial trajectory cannot be produced to the standard required for investment or R&D resource allocation.

What drives demand for PROSTIN F2 ALPHA?

Demand for prostaglandin F2α products is primarily dictated by:

• Indication specificity: Use is typically tied to reproductive health and obstetric or gynecologic workflows (historically including labor induction and cervical ripening contexts, plus other procedure-linked uses depending on local label). This keeps addressable patient volumes narrower than broad-spectrum drug classes.
• Formulation and administration workflow: Dinoprost formulations influence uptake based on route, setting (inpatient vs outpatient), and clinic protocols.
• Protocol substitution: Clinicians often switch among prostaglandin analogs or alternatives depending on efficacy profile, tolerability, guideline position, and availability.
• Supply continuity and manufacturing: Specialty injectables are sensitive to batch releases, quality events, and manufacturing throughput.
• Pricing and reimbursement mechanics: Where payers bundle procedure-related costs, drug reimbursement pressure can be indirect but still material.

How does competition reshape pricing power?

Competitive dynamics for prostaglandin F2α brands typically follow these patterns:

• Class-level substitution: Other prostaglandin agents (different chemical entities and formulations) compete for the same clinical decision point.
• Generic entry risk: If local regulatory regimes support generic substitution for the active and formulation strength, branded pricing tends to compress.
• Tendering and hospital contracting: In hospital-led utilization models, procurement cycles can drive step-down pricing even without formal generic entry, via bid wins and alternative stock preference.

The practical consequence for a brand like PROSTIN F2 ALPHA is a financial profile that looks less like “revenue compounding” and more like “usage maintenance with periodic price compression.”

What is the likely market lifecycle stage?

Without a validated, market-by-market evidence base for current sales and competitive structure, the most defensible characterization is:

• Mid-to-late lifecycle in mature markets if generics or equivalent prostaglandin alternatives exist.
• Steady demand in pockets where label-specific positioning and established clinician protocols maintain baseline usage.
• Growth constraints where competing protocols (other prostaglandins or non-prostaglandin induction strategies) gain guideline share.

This lifecycle pattern aligns with specialty injectables where clinical adoption is slower than in consumer-like markets and where competitors can lock in formularies.

What does the revenue curve usually look like for prostaglandin F2α brands?

A typical financial trajectory for a niche specialty injectable brand has four phases:

1. Pre-generic runway: Higher pricing with stable utilization.
2. Erosion onset: Inflection when generic or alternative branded competition appears in the same therapeutic niche.
3. Portfolio consolidation: Demand shifts to fewer formulary positions and contracted SKUs.
4. Flooring effect: Residual sales persist at lower net prices due to entrenched workflow compatibility.

For PROSTIN F2 ALPHA, the key variable that determines where it sits on this curve is the current existence and market share of generics and substitutable prostaglandins in the target geography.

What role do patents and exclusivity play in the financial trajectory?

For injectable specialty drugs, patent and exclusivity determine the depth and duration of pricing protection. The financial outcome is typically a function of:

• Whether composition-of-matter or formulation/process patents cover the marketed dinoprost tromethamine product in each jurisdiction.
• Whether regulatory exclusivities (if any) have already expired in the same jurisdictions.
• Whether competing products launch as authorized generics, 505(b)(2-style reformulations, or full generics, affecting net price and volume share.

Absent a jurisdiction-specific patent estate map for the exact PROSTIN F2 ALPHA presentation and approval history, a precise link between exclusivity expiry dates and revenue inflection cannot be stated with required factual rigor.

How should investors interpret “market dynamics” signals?

Signals that most often correlate with near-term financial movement for niche injectable brands:

• Hospital formulary changes (contract award cycles).
• Guideline updates for induction and obstetric management.
• Competitive launches of other prostaglandins or alternative clinical strategies.
• Drug availability events that affect stocking and clinician trust.
• Regulatory actions that restrict or broaden labeled indications.

For PROSTIN F2 ALPHA, the market will react quickly to procurement and guideline shifts because the product’s usage is decision-driven and setting-driven.

---

Key Takeaways

• PROSTIN F2 ALPHA is a niche specialty injectable with demand concentrated in specific clinical workflows, limiting addressable volume relative to blockbuster therapeutic areas.
• Market dynamics are dominated by substitution within prostaglandins, generic erosion risk, and hospital contracting rather than broad outpatient consumer-style adoption.
• The financial trajectory for this drug class typically follows a post-exclusivity erosion pattern, with revenue stabilizing at lower net prices if residual formulary inclusion persists.
• A number-based revenue and forecast cannot be produced from the brand name alone without an exact, jurisdiction-linked product identification and sales dataset.

---

FAQs

1) Is PROSTIN F2 ALPHA a blockbuster-style revenue generator?

No. Its market is typically constrained by indication specificity and hospital/clinical workflow dependence rather than widespread chronic outpatient use.

2) What most threatens the brand financially?

Generic entry or formulary substitution by alternative prostaglandin products that address the same clinical decision point.

3) What most supports continued demand?

Entrenched clinician and hospital protocol fit, stable availability, and persistence of labeled use in key jurisdictions.

4) Are revenue changes driven more by price or by volume?

Often by net price compression from contracting and substitution, with volume changes secondary and driven by formulary position and guideline adherence.

5) How do patents typically show up in the financial history?

As inflection points when exclusivity expires and competitors launch, followed by sustained residual sales if the brand retains limited formulary coverage.

---

References

[1] FDA. “Drug Approval Package: PROSTIN F2 ALPHA” (search results depend on exact product and application).
[2] EMA. European public assessment reports for dinoprost-containing products (search depends on exact trade name and MAH).
[3] USPTO / EPO. Patent family records for dinoprostone/dinoprost tromethamine and formulation/process claims (search depends on exact marketed salt and presentation).